A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models
Stabach P, Sims D, Gomez-Bañuelos E, Zehentmeier S, Dammen-Brower K, Bernhisel A, Kujawski S, Lopez S, Petri M, Goldman D, Lester E, Le Q, Ishaq T, Kim H, Srivastava S, Kumar D, Pereira J, Yarema K, Koumpouras F, Andrade F, Braddock D. A dual-acting DNASE1/DNASE1L3 biologic prevents autoimmunity and death in genetic and induced lupus models. JCI Insight 2024, 9: e177003. PMID: 38888971, PMCID: PMC11383374, DOI: 10.1172/jci.insight.177003.Peer-Reviewed Original ResearchSystemic lupus erythematosusDNASE1L3 deficiencySporadic systemic lupus erythematosusAssociated with systemic lupus erythematosusChromatin degradationDNA accumulationDevelopment of lupusPristane-induced lupusSelf-DNACell free DNAHuman isoformsSystemic lupus erythematosus plasmasDouble knockout miceDNASE1L3Pathogenic effectsFree DNALupus modelEnzymeInducible lupus modelAdult patientsLupus erythematosusKnockout micePediatric populationAutoimmune diseasesDNAChimeric antigen receptors: “CARs” in the fast lane for rheumatology
Johnson N, Koumpouras F. Chimeric antigen receptors: “CARs” in the fast lane for rheumatology. Current Opinion In Rheumatology 2024, 36: 176-183. PMID: 38517338, PMCID: PMC11224568, DOI: 10.1097/bor.0000000000001012.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorCAR-T treatmentCAR-TB cellsAutoimmune diseasesRheumatologic diseasesReview current clinical dataSevere refractory autoimmune diseasesReconstitution of B cellsRefractory autoimmune diseasesTreatment of rheumatologic diseasesB-cell malignanciesCompassionate use programB cell populationsLaboratory remissionRefractory SLECD19-CARField of autoimmunityRefractory diseaseClinical responseNaive phenotypeSevere lupusMultiple myelomaAutoimmune modelsT cells